Novartis AG

OTC: NVSEF · Real-Time Price · USD
115.50
0.00 (0.00%)
At close: Aug 11, 2025, 11:49 AM

Novartis Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
51.72B 46.66B 51.83B 52.88B
Cost of Revenue
12.83B 12.02B 15.49B 15.87B
Gross Profit
38.9B 34.64B 36.34B 37.01B
Operating Income
14.54B 9.77B 9.2B 11.69B
Interest Income
550.78M 436M 389.37M 71.15M
Pretax Income
13.64B 9.12B 8.37B 26.14B
Net Income
11.94B 14.85B 6.96B 24.02B
Selling & General & Admin
12.57B 12.49B 14.25B 14.89B
Research & Development
10.02B 11.37B 10B 9.54B
Other Expenses
1.76B 1.01B -101.22M 269.57M
Operating Expenses
24.35B 24.87B 27.14B 25.32B
Interest Expense
1.01B 855M 860.33M 906.93M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
37.18B 36.89B 42.63B 41.19B
Income Tax Expense
1.7B 551M 1.42B 2.12B
Shares Outstanding (Basic)
2.02B 2.08B 2.18B 2.24B
Shares Outstanding (Diluted)
2.04B 2.09B 2.2B 2.26B
EPS (Basic)
5.92 7.63 3.29 10.73
EPS (Diluted)
5.87 7.58 3.27 10.65
EBITDA
20.71B 19.52B 15.21B 17.17B
EBIT
14.65B 10.68B 8.28B 11.73B
Depreciation & Amortization
6.07B 8.83B 6.92B 5.44B